Abstract

Disease-specific markers are critical for early diagnosis, targeted therapy and prognostic prediction of diseases. Current study reports a complex microsatellite as a new prognostic marker of sporadic colorectal cancer. This microsatellite located at Chromosome 7q33 is composed of three tetranucleotide tandem repeats, (TTCC)2(TCCC)5(TCCT)7, flanked by a CT-rich sequence. We analyzed polymorphisms of this microsatellite in 158 sporadic colorectal cancer, 143 matched normal adjacent tissues (NAT) and 150 health donors. Our results showed that this complex microsatellite was instable with polymorphic frequency of 77.2% in colorectal cancer, 52.4% in NAT and 54.7% in health donors (p<0.01) when compared to reference sequence. In the three tandem repeats, (TCCT)7 site was most polymorphic accounting for over 70.0% of polymorphisms in this complex microsatellite, followed by (TTCC)2 site for approximately 20%. Polymorphisms in (TCCC)5 was rare. Polymorphisms at the (TCCT)7 site were mainly insertions of 1 to 4 copies of TCCT (88.6%), and deletions occurred in about 6.4% of cases. The (TTCC)2 site was featured with one copy TTCC insertions. Pair-wise analyses between colorectal tumors and NAT revealed that 88 of 121 (72.7%) tumors displayed expansion, contraction or both in these tetranucleotide tandem repeats when compared to NAT. A cross-analysis with clinicopathological data of 158 colorectal cancers revealed that polymorphic alterations of the microsatellite associated with less lymphatic metastasis (p<0.001), and the colorectal cancer patients with polymorphic changes in this microsatellite demonstrated better survival (n=112, p=0.0058). Together these data suggest that this complex microsatellite is a potential prognostic marker of sporadic colorectal cancer.

Highlights

  • Colorectal cancer (CRC) is a leading cause of cancer-related deaths in the United States; approximately 1 in 19 Americans (5.29%) will suffer from colorectal cancer during their life-time [1]

  • Our results showed that this complex microsatellite was instable with polymorphic frequency of 77.2% in colorectal cancer, 52.4% in normal adjacent tissues (NAT) and 54.7% in health donors (p

  • 75% of colorectal cancer develops among people free of inflammatory bowel disease (IBD) and a familial history of hereditary non-polyposis colorectal cancer (HNPCC), colorectal neoplasia, or familial adenomatous polyposis (FAP), so called sporadic colorectal cancer

Read more

Summary

Introduction

Colorectal cancer (CRC) is a leading cause of cancer-related deaths in the United States; approximately 1 in 19 Americans (5.29%) will suffer from colorectal cancer during their life-time [1]. 75% of colorectal cancer develops among people free of IBD and a familial history of hereditary non-polyposis colorectal cancer (HNPCC), colorectal neoplasia, or familial adenomatous polyposis (FAP), so called sporadic colorectal cancer. This makes the early diagnosis difficult due to lack of screening [7,8,9,10]. It is needed to identify and validate non-invasive, affordable, highly sensitive and specific biomarkers for screening and early diagnosis and/or prognostic prediction of colorectal cancer to improve the clinical management of this lethal disease

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call